GALT— GALECTIN THERAPEUTICS INC

MaterialsPharmaceutical Preparations$227M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Research and development	$14.3M-60.9%	$36.6M+13.8%	$32.1M+1.2%	$31.7M
General and administrative	$5.8M-1.1%	$5.9M-1.3%	$5.9M-10.2%	$6.6M
Total operating expenses	$20.1M-52.7%	$42.4M+11.5%	$38.1M-0.7%	$38.4M
Total operating loss	-$20.1M+52.7%	-$42.4M-11.5%	-$38.1M+0.7%	-$38.4M
Interest income	$126K-62.7%	$338K+47.0%	$230K+342.3%	$52K
Interest expense	-$7.3M-32.3%	-$5.5M-98.4%	-$2.8M-170.3%	-$1.0M
Change in fair value of derivatives	-$3.5M-703.4%	$588K+236.1%	-$432K-177.6%	$557K
Total other expense	-$10.8M-133.0%	-$4.6M-54.1%	-$3.0M-606.1%	-$424K
Net loss	-$30.8M+34.5%	-$47.0M-14.6%	-$41.1M-5.9%	-$38.8M
Preferred stock dividends	-$138K+9.8%	-$153K-27.5%	-$120K-23.7%	-$97K
Net loss applicable to common stockholders	-$31.0M+34.4%	-$47.2M-5.3%	-$44.8M-15.3%	-$38.9M
Net loss per common share - basic (in Dollars per share)	-$480.00+36.8%	-$760.00-2.7%	-$740.00-13.8%	-$650.00
Net loss per common share - diluted (in Dollars per share)	-$480.00+36.8%	-$760.00-2.7%	-$740.00-13.8%	-$650.00
Weighted average common and potential common shares outstanding - basic (in Shares)	63.9M+2.6%	62.3M+3.6%	60.2M+1.3%	59.4M
Weighted average common and potential common shares outstanding - diluted (in Shares)	63.9M+2.6%	62.3M+3.6%	60.2M+1.3%	59.4M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.